Markets:

Overview

News

Currencies

International

Treasuries

Erasca, Inc. - Common Stock (NQ:ERAS)

11.24 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Erasca, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.

May 19, 2026

From Kirby McInerney LLP

Via Business Wire

ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm

May 19, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

May 19, 2026

From Pomerantz LLP

Via GlobeNewswire

Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗

May 18, 2026

This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates.

Via The Motley Fool

Topics Regulatory Compliance

Erasca (NASDAQ:ERAS) Beats Q1 Estimates on Promising ERAS-0015 Data ↗

May 11, 2026

Via Chartmill

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗

May 17, 2026

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.

Via The Motley Fool

Topics Regulatory Compliance

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗

May 17, 2026

This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.

Via The Motley Fool

Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗

May 17, 2026

This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.

Via The Motley Fool

Topics Regulatory Compliance

Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference ↗

May 16, 2026

Erasca (NASDAQ:ERAS) executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic and...

Via MarketBeat

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗

May 16, 2026

This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.

Via The Motley Fool

Topics Regulatory Compliance

ERAS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

May 14, 2026

From Kirby McInerney LLP

Via GlobeNewswire

ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm

May 14, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗

May 14, 2026

Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗

May 14, 2026

Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach.

Via The Motley Fool

Topics Initial Public Offering

Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗

May 14, 2026

This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types.

Via The Motley Fool

Topics Regulatory Compliance

ERASCA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

May 12, 2026

From Kirby McInerney LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

May 12, 2026

From Pomerantz LLP

Via GlobeNewswire

ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm

May 10, 2026

From Schall Law

Via GlobeNewswire

Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial ↗

April 28, 2026

Today, April 28, 2026, investors are weighing how a trial death will reshape Erasca's investment thesis.

Via The Motley Fool

Topics Stocks

Here are the top movers in Tuesday's session. ↗

April 28, 2026

Via Chartmill

Which stocks are experiencing notable movement on Tuesday? ↗

April 28, 2026

Via Chartmill

Gapping stocks in Tuesday's session ↗

April 28, 2026

Via Chartmill

Top movers in Tuesday's pre-market session ↗

April 28, 2026

Via Chartmill

What's going on in today's after hours session ↗

April 27, 2026

Via Chartmill

Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't ↗

March 26, 2026

This oncology biotech, developing targeted cancer therapies, reported a notable insider sale following a remarkable year for its stock.

Via The Motley Fool

Topics Regulatory Compliance

Registration Momentum Builds Across the Oncology Pipeline

February 17, 2026

Issued on behalf of Oncolytics Biotech Inc.

From USA News Group

Via GlobeNewswire

Erasca (ERAS) Stock Slides After The Bell: Here's Why ↗

January 20, 2026

Erasca Inc (NASDAQ:ERAS) shares are moving lower in extended trading Tuesday after the company announced a proposed public offering.

Via Benzinga

Erasca Insider Sells $671K as Stock Jumps 189% This Past Year ↗

January 13, 2026

This oncology biotech developing targeted cancer therapies saw a key insider significantly trim their direct equity stake.

Via The Motley Fool

Topics Regulatory Compliance

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

January 08, 2026

Via Chartmill

The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader

January 08, 2026

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...

Via MarketMinute

Topics Intellectual Property

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.